|
Biotest AG / Key word(s): Preliminary Results
Biotest AG: Biotest exceeds already raised EBIT guidance
26-Feb-2020 / 17:11 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
/
Ad-hoc RELEASE
Announcement according to Article 17 European Market Abuse Regulation (MAR)
Biotest exceeds already raised EBIT guidance
Dreieich, 26 February 2020. According to preliminary and unaudited figures, the Biotest AG generated in the 2019 financial year revenue of € 419.1 million (+4.7%) compared to € 400.3 million in the previous year.
EBIT amounted to € -1.2 million in the 2019 financial year, compared with € 10.6 million in the previous year. The raised EBIT guidance of
€ -3 to -13 million was thus exceeded. The year-on-year decline in EBIT is due to higher expenses for the expansion of production capacity at the Dreieich site (Biotest Next Level) and the associated higher research and development expenses for the new products.
Biotest will publish final results for the financial year 2019 and the annual report on 30 March 2020. The Annual General Meeting of Biotest AG will take place on 8 May 2020 in Frankfurt/Main.
Biotest Aktiengesellschaft
Board of Management
Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.com
Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
Contact:
Dr. Michael Ramroth
Chief Financial Officer
Biotest AG
Landsteinerstr. 3
63303 Dreieich
Tel. +40 6103 801 338
Fax: +49 6103 801 347
Michael.ramroth@biotest.com
26-Feb-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
|
